BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Queiroz NSF, Saad-Hossne R, FrÓes RSB, Penna FGCE, Gabriel SB, Martins AL, Teixeira FV. DISCONTINUATION RATES FOLLOWING A SWITCH FROM A REFERENCE TO A BIOSIMILAR BIOLOGIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. Arq Gastroenterol 2020;57:232-43. [PMID: 32935741 DOI: 10.1590/S0004-2803.202000000-45] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Shubow S, Sun Q, Nguyen Phan AL, Hammell DC, Kane M, Lyman GH, Gibofsky A, Lichtenstein GR, Bloomgarden Z, Cross RK, Yim S, Polli JE, Wang YM. Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary. Clin Pharmacol Ther 2023;113:37-49. [PMID: 36251545 DOI: 10.1002/cpt.2765] [Reference Citation Analysis]
2 Dutt K, Srinivasan A, Van Langenberg D. The Nocebo Effect in a Non-Medical Switching Program from Originator to Biosimilar Infliximab in Inflammatory Bowel Disease. BioDrugs 2022. [PMID: 35960446 DOI: 10.1007/s40259-022-00548-4] [Reference Citation Analysis]
3 Rodrigues de Figueiredo S, Elisa Rabe Caon A, Saad Hossne R, Vieira Teixeira F, Murakami Winkler S, Sousa Freitas Queiroz N. Biosimilars in Inflammatory Bowel Diseases: General Concepts and Clinical Implications. Biosimilars 2022. [DOI: 10.5772/intechopen.100452] [Reference Citation Analysis]
4 Parrish RH. Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary. Gastroenterology Insights 2021;12:293-301. [DOI: 10.3390/gastroent12030026] [Reference Citation Analysis]
5 Panaccione R. The Great Debate With IBD Biosimilars: Con: Biosimilars Should Not Be Routinely Used as a First Line Biologic and Not Switched From Reference Biologics. Crohns Colitis 360 2021;3:otab038. [PMID: 36776671 DOI: 10.1093/crocol/otab038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Garcia KS, Facas BP, Machado MB, Teixeira FV, Avedano L, Lönnfors S, Hossne RS, Peyrin-Biroulet L, Queiroz NSF. Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients. Therap Adv Gastroenterol 2021;14:17562848211013249. [PMID: 34046083 DOI: 10.1177/17562848211013249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Khan N, Patel D, Pernes T, Patel M, Trivedi C, Medvedeva E, Xie D, Yang YX. The Efficacy and Safety of Switching From Originator Infliximab to Single or Double Switch Biosimilar Among a Nationwide Cohort of Inflammatory Bowel Disease Patients. Crohns Colitis 360 2021;3:otab022. [PMID: 36778941 DOI: 10.1093/crocol/otab022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kotze PG, DamiÃo AOMC. Research in inflammatory bowel disease in Brazil: a step forward towards patient care. Arq Gastroenterol 2020;57:225-6. [PMID: 33206810 DOI: 10.1590/S0004-2803.202000000-43] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]